Deferasirox

FDA Approved: * January 26, 2016
Pharm Company: * ACTAVIS ELIZABETH
Category: Iron Chelator

Deferasirox, sold under the brand name Exjade & Asunra (in injectable form) & Oleptiss (Tablet formulation) both by Novartis among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.[2][3] It is the first oral medication approved in the United States for this purpose.[4] It was appro... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Jadenu 90 mg Oral Tablet, Film Coated
NDC: 0078-0654
Labeler:
Novartis Pharmaceuticals Corporation
Jadenu 180 mg Oral Tablet, Film Coated
NDC: 0078-0655
Labeler:
Novartis Pharmaceuticals Corporation
Jadenu 360 mg Oral Tablet, Film Coated
NDC: 0078-0656
Labeler:
Novartis Pharmaceuticals Corporation
Deferasirox 360 mg Oral Tablet
NDC: 0093-3515
Labeler:
Teva Pharmaceuticals USA, Inc.
Deferasirox 180 mg Oral Tablet, Film Coated
NDC: 0093-3516
Labeler:
Teva Pharmaceuticals USA, Inc.
Deferasirox 90 mg Oral Tablet
NDC: 0093-3517
Labeler:
Teva Pharmaceuticals USA, Inc.
Deferasirox 180 mg Oral Tablet, Film Coated
NDC: 0591-3853
Labeler:
Actavis Pharma, Inc.
Deferasirox 90 mg Oral Tablet, Film Coated
NDC: 16714-993
Labeler:
Northstar Rx LLC.
Deferasirox 180 mg Oral Tablet, Film Coated
NDC: 16714-994
Labeler:
Northstar Rx LLC.
Deferasirox 360 mg Oral Tablet, Film Coated
NDC: 16714-995
Labeler:
Northstar Rx LLC.

Related Brands

Drugs with the same active ingredients